Trial Profile
An open label study to evaluate pharmacokinetics of a Novel orally disintegrating Amphetamine Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Aug 2017
Price :
$35
*
At a glance
- Drugs Amfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacokinetics
- 24 Aug 2017 New trial record